Our Science – Kreitman Website
Robert J. Kreitman, M.D.
Selected Publications |
 |
| 1)
Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk. Res. 37: 401-9, 2013. [Journal] |
|
| 2)
Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 119: 3330-2, 2012. [Journal] |
|
| 3)
Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology Am Soc Hematol Educ Program. 2012: 660-6, 2012. [Journal] |
|
| 4)
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. J. Clin. Oncol. 30: 1822-8, 2012. [Journal] |
|
| 5)
Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. Blood. 120: 1816-9, 2012. [Journal] |
|
| 6)
Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012. [Journal] |
|
| 7)
Singh R, Zhang Y, Pastan I, Kreitman RJ. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin. Cancer Res. 18: 152-60, 2012. [Journal] |
|
| 8)
Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Büschenfelde C, Ringshausen I. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion. Haematologica. 97: 771-9, 2012. [Journal] |
|
| 9)
Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res. 17: 6398-405, 2011. [Journal] |
|
| 10)
Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am. J. Clin. Pathol. 136: 625-30, 2011. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/16/2013.
